Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Shiraz Transplant Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Hum Reprod. 2019 Dec 1;34(12):2430-2442. doi: 10.1093/humrep/dez196.
Could small molecules (SM) which target (or modify) signaling pathways lead to increased proliferation of undifferentiated spermatogonia following chemotherapy?
Inhibition of transforming growth factor-beta (TGFb) signaling by SM can enhance the proliferation of undifferentiated spermatogonia and spermatogenesis recovery following chemotherapy.
Spermatogonial stem cells (SSCs) hold great promise for fertility preservation in prepubertal boys diagnosed with cancer. However, the low number of SSCs limits their clinical applications. SM are chemically synthesized molecules that diffuse across the cell membrane to specifically target proteins involved in signaling pathways, and studies have reported their ability to increase the proliferation or differentiation of germ cells.
STUDY DESIGN, SIZE, DURATION: In our experimental study, spermatogonia were collected from four brain-dead individuals and used for SM screening in vitro. For in vivo assessments, busulfan-treated mice were treated with the selected SM (or vehicle, the control) and assayed after 2 (three mice per group) and 5 weeks (two mice per group).
PARTICIPANTS/MATERIALS, SETTING, METHODS: We investigated the effect of six SM on the proliferation of human undifferentiated spermatogonia in vitro using a top-bottom approach for screening. We used histological, hormonal and gene-expression analyses to assess the effect of selected SM on mouse spermatogenesis. All experiments were performed at least in triplicate and were statistically evaluated by Student's t-test and/or one-way ANOVA followed by Scheffe's or Tukey's post-hoc.
We found that administration of SB431542, as a specific inhibitor of the TGFb1 receptor (TGFbR1), leads to a two-fold increase in mouse and human undifferentiated spermatogonia proliferation. Furthermore, injection of SB to busulfan-treated mice accelerated spermatogenesis recovery as revealed by increased testicular size, weight and serum level of inhibin B. Moreover, SB administration accelerated both the onset and completion of spermatogenesis. We demonstrated that SB promotes proliferation in testicular tissue by regulating the cyclin-dependent kinase (CDK) inhibitors 4Ebp1 and P57 (proliferation inhibitor genes) and up-regulating Cdc25a and Cdk4 (cell cycle promoting genes).
LIMITATIONS, REASONS FOR CAUTION: The availability of human testis was the main limitation in this study.
This is the first study to report acceleration of spermatogenesis recovery following chemotherapy by administration of a single SM. Our findings suggest that SB is a promising SM and should be assessed in future clinical trials for preservation of fertility in men diagnosed with cancer or in certain infertility cases (e.g. oligospermia).
STUDY FUNDING/COMPETING INTEREST(S): This study was supported by Royan Institute and National Institute for Medical Research Development (NIMAD, grant no 963337) granted to H.B. The authors have no conflict of interest to report.
针对(或修饰)信号通路的小分子(SM)是否会导致化疗后未分化精原细胞增殖增加?
SM 抑制转化生长因子-β(TGFb)信号可以增强未分化精原细胞的增殖,并促进化疗后精子发生的恢复。
精原干细胞(SSC)在诊断为癌症的青春期前男孩的生育力保存方面具有巨大的应用前景。然而,SSC 的数量很少限制了它们的临床应用。SM 是化学合成的分子,可穿过细胞膜扩散,专门针对参与信号通路的蛋白质,研究报告称它们具有增加生殖细胞增殖或分化的能力。
研究设计、大小、持续时间:在我们的实验研究中,从四名脑死亡个体中收集精原细胞,并在体外进行 SM 筛选。对于体内评估,用白消安处理的小鼠用选定的 SM(或载体,对照)处理,并在 2 周(每组 3 只小鼠)和 5 周(每组 2 只小鼠)后进行分析。
参与者/材料、设置、方法:我们使用上下法进行筛选,研究了六种 SM 对体外未分化人精原细胞增殖的影响。我们使用组织学、激素和基因表达分析来评估选定 SM 对小鼠精子发生的影响。所有实验均至少重复三次,并通过学生 t 检验和/或单向方差分析(随后是 Scheffe 或 Tukey 的事后检验)进行统计学评估。
我们发现,作为 TGFb1 受体(TGFbR1)的特异性抑制剂,SB431542 的给药导致小鼠和人未分化精原细胞增殖增加一倍。此外,SB 注射到白消安处理的小鼠中加速了精子发生的恢复,表现为睾丸大小、重量和抑制素 B 血清水平增加。此外,SB 给药加速了精子发生的开始和完成。我们证明,SB 通过调节细胞周期蛋白依赖性激酶(CDK)抑制剂 4Ebp1 和 P57(增殖抑制剂基因)并上调 Cdc25a 和 Cdk4(细胞周期促进基因)来促进睾丸组织中的增殖。
局限性、谨慎的原因:本研究的主要限制是人类睾丸的可用性。
这是第一项报告通过单一 SM 给药加速化疗后精子发生恢复的研究。我们的研究结果表明,SB 是一种很有前途的 SM,应该在未来的临床试验中进行评估,以保存诊断为癌症或某些不育症(如少精症)的男性的生育能力。
研究资金/利益冲突:本研究由 Royan 研究所和国家医学研究发展研究所(NIMAD,授予号 963337)资助。作者没有利益冲突需要报告。